Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3727_Библиотеки_им_академика_М_И_Перельмана
.pdf
264 Chapter 25 Prevention of deep venous thrombosis
https://t.me/med1917
derive a composite score. Once the assessment is complete,
the patient is assigned to a specic risk level (Table25.2)
that recommends risk-commensurate prophylaxis.
Electronic order sets can be created to mandate (with
“hard stops”) that a Caprini score be completed before
admission or preoperative orders are nalized, and this
step can also be required after the operation and upon
discharge. Order sets can be customized to automatically
display the recommended course of prophylaxis. To be
clear, this sort of system mandates the calculation of scores
for each patient, although it does not mandate the selection
of prophylaxis. Clinicians may still opt out of pharmacological prophylaxis if contraindications exist, and the system can prompt documentation for declining. This design
allows electronic monitoring of protocol compliance and
reasons for nonadherence to guidelines.
TABLE 25.2 Risk assessment and prophylaxis based on Caprini Risk Score
Caprini score Risk category Recommended prophylaxis Recommended duration
0 Lowest Early frequent ambulation only OR at discretion of surgical team:
compression boots OR low-dose heparin OR low-molecular-weight
heparin
1–2 Low Compression boots OR low-dose heparin OR low-molecular-weight
heparin (choose 1 item)
3–4 Moderate Compression boots AND low-dose heparin OR low-molecular-weight
heparin (choose 1 medication)
5–8 High Compression boots AND low-dose heparin OR low-molecular-weight
heparin (choose 1 medication)
≥9 Highest Compression boots AND low-dose heparin OR low-molecular-weight
heparin (choose 1 medication)
of chemoprophylaxis
During hospitalization
During hospitalization
During hospitalization
7–10 days total
30 days total
Guidelines 25.0 of the American Venous Forum on prevention of deep venous thrombosis*
No. Guideline Grade
25.1 We recommend a thorough assessment of VTE risk factors among patients undergoing operations, upon hospital admission, and throughout the perioperative phases.
25.2 We recommend VTE risk stratication of patients prior to outpatient operations. 1
25.3 We recommend VTE risk assessment upon hospital admission for medical patients. 1
25.4 We recommend mechanical prophylaxis, including early ambulation, for the patients
at lowest risk for VTE.
25.5 We recommend mechanical prophylaxis in addition to pharmacological prophylaxis
for patients who have at least a moderate risk for VTE.
25.6 We suggest against extended courses of pharmacological prophylaxis beyond hospital discharge for most nonsurgical patients.
25.7 We recommend extended courses of pharmacological prophylaxis for high- and
highest-risk surgical patients.
25.8 We recommend against routine IVC lter placement for VTE prophylaxis. 1
* Based on guidelines of the ACCP
3,4,8
and the ACH.
34
of recommendation
1
(strong)
(strong)
(strong)
1
(strong)
1
(strong)
2
(weak)
1
(strong)
(strong)
REFERENCES
★ Systematic review
♦ Guidelines
1. Shojania KG, Duncan BW, McDonald
KM, Wachter RM, Markowitz AJ.
Making health care safer: Acritical
analysis of patient safety practices. Evid
Rep Technol Assess (Summ). 2001;43:i–x,
1–668.
2. Wilson S, Chen X, Cronin M, Dengler
N, Enker P, Krauss ES, etal. Thrombosis
prophylaxis in surgical patients using the
Caprini Risk Score. Curr Probl Surg. 2022
Nov;59(11):101221.
♦
3. Kahn SR, Lim W, Dunn AS, Cushman
M, Dentali F, Akl EA, etal. Prevention of
VTE in nonsurgical patients: Antithrombotic therapy and prevention of throm-
bosis, 9th ed: American college of chest
physicians evidence-based clinical practice
guidelines. Chest. 2012 Feb;141(2 Suppl):
e195S–e226S.
♦
4. Falck-Ytter Y, Francis CW, Johanson NA,
Curley C, Dahl OE, Schulman S, e al.
Prevention of VTE in orthopedic surgery
patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American
Quality
of evidence
A
(high)
B
(moderate)
B
(moderate)
B
(moderate)
B
(moderate)
B
(moderate)
B
(moderate)
B
(moderate)

References 265
https://t.me/med1917
college of chest physicians evidence-based
clinical practice guidelines. Chest. 2012
Feb;141(2 Suppl):e278S–e325S.
5. Bahl V, Hu HM, Henke PK, Wakeeld
TW, Campbell DA Jr, Caprini JA. Avalidation study of a retrospective venous
thromboembolism risk scoring method.
Ann Surg. 2010 Feb;251(2):344–50.
6. Caprini JA, Arcelus JI, Hasty JH,
Tamhane AC, Fabrega F. Clinical assessment of venous thromboembolic risk in
surgical patients. Semin Thromb Hemost.
1991;17(3 Suppl):304–12.
7. Rogers SO Jr, Kilaru RK, Hosokawa P,
Henderson WG, Zinner MJ, Khuri SF.
Multivariable predictors of postoperative
venous thromboembolic events after general and vascular surgery: Results from the
patient safety in surgery study. J Am Coll
Surg. 2007 Jun;204(6):1211–21.
♦8. Gould MK, Garcia DA, Wren SM, Kara-
nicolas PJ, Arcelus JI, Heit JA, etal. Prevention of VTE in nonorthopedic surgical
patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American
college of chest physicians evidence-based
clinical practice guidelines. Chest. 2012
Feb;141(2 Suppl):e227S–e277S.
♦9. Garcia DA., Baglin TP., Weitz JI,
Samama MM. American college of Chest
physicians. Parenteral anticoagulants:
Antithrombotic therapy and prevention of
thrombosis, 9th ed: American college of
Chest physicians evidence-based clinical
practice guidelines. Chest. 2012;141(2
Suppl):e24S–e43S.
♦10. Geerts WH, Bergqvist D, Pineo GF, Heit
JA, Samama CM, Lassen MR, Colwell
CW. Prevention of venous thromboembolism: American college of Chest physicians
evidence-based clinical practice guidelines
(8th Edition). Chest. 2008 Jun;133(6
Suppl):381S–453S.
11. Pannucci CJ, Fleming KI. Comparison of
face-to-face interaction and the electronic
medical record for venous thromboembolism risk stratication using the 2005
Caprini score. J Vasc Surg Venous Lymphat Disord. 2018 May;6(3):304–11.
12. Hasley RB, Aly S, Carter CO, Carmine B,
Hess DT, McAneny D, Pernar LI. Application of the Caprini Risk assessment model
to select patients for extended thromboembolism prophylaxis after sleeve
gastrectomy. J Gastrointest Surg. 2022
Feb;26(2):298–304.
★13. Rausa E, Kelly ME, Asti E, etal. Extended
versus conventional thromboprophylaxis
after major abdominal and pelvic surgery:
Systematic review and meta-analysis
of randomized clinical trials. Surgery.
2018;164(6):1234–40.
★14. Fagarasanu A, Alotaibi GS, Hrimiuc
R, Lee AYY, Wu C. Role of extended
thromboprophylaxis after abdominal
and pelvic surgery in Cancer patients:
Asystematic review and meta-analysis.
Ann Surg Oncol. 2016;23(5):1422–30.
doi: 10.1245/s10434-016-5127-1
15. Gemma M, Pennoni F, Braga M.
Studying Enhanced Recovery After Surgery (ERAS
gery: Acausal model with latent variables.
World J Surg. 2021 Apr;45(4):928–39.
®
) core items in colorectal sur-
16. Vaughn SC, Talutis SD, Cassidy MR,
Sachs TE, Drake FT, Rosenkranz P, etal.
Two novel risk factors for postoperative
venous thromboembolism: Areconsideration of standard risk assessment
and prophylaxis. Am J Surg. 2020
Nov;220(5):1338–43.
17. Galbraith EM, Vautaw BM, Grzybowski
M, Henke PK, Wakeeld TW, Froehlich
JB. Variation in physician deep vein
thrombosis prophylaxis attitudes and
practices at an academic tertiary care
center. J Thromb Thrombolysis. 2010
Nov;30(4):419–25. doi: 10.1007/s11239010-0455-7. PMID: 20174856.
18. Cassidy MR, Macht RD, Rosenkranz
P, Caprini JA, McAneny D. Patterns of
failure of a Standardized perioperative
venous thromboembolism prophylaxis protocol. J Am Coll Surg. 2016
Jun;222(6):1074–80. doi: 10.1016/j.
jamcollsurg.2015.12.022. Epub 2015 Dec
24. PMID: 26821972.
19. Cassidy MR, Rosenkranz P, McAneny
D. Reducing postoperative venous
thromboembolism complications with a
standardized risk-stratied prophylaxis
protocol and mobilization program. J Am
Coll Surg. 2014 Jun;218(6):1095–104.
20. Sachdeva A, Dalton M, Lees T. Graduated
compression stockings for prevention of
deep vein thrombosis. Cochrane Database
Syst Rev. 2018 Nov 3;11(11):CD001484.
21. Ho KM, Tan JA. Stratied meta-analysis
of intermittent pneumatic compression of
the lower limbs to prevent venous thromboembolism in hospitalized patients. Circulation. 2013 Aug 27;128(9):1003–1020.
★22. Lott N, Robb F, Nolan E, Attia J, Reeves
P, Gani J, Smith S. Efcacy of intermittent
compression devices for thromboembolic
prophylaxis in major abdominal surgery:
Asystematic review and meta-analysis.
ANZ J Surg. 2022 Nov;92(11):2926–34.
23. Siracuse JJ, Al Bazroon A, Gill HL,
Meltzer AJ, Schneider DB, Parrack I, etal.
Risk factors of nonretrieval of retrievable
inferior vena cava lters. Ann Vasc Surg.
2015 Feb;29(2):318–21. doi: 10.1016/j.
avsg.2014.08.008. Epub 2014 Oct 13.
PMID: 25308241.
24. Charalel RA, Durack JC, Mao J, Ross
JS, Meltzer AJ, Sedrakyan A. Statewide
inferior vena cava lter placement,
complications, and retrievals: Epidemiology and recent trends. Med Care.
2018 Mar;56(3):260–5. doi: 10.1097/
MLR.0000000000000867. PMID:
29356721.
♦25. Kaufman JA, Barnes GD, Chaer RA,
Cuschieri J, Eberhardt RT, Johnson MS,
etal. Society of interventional radiology
clinical practice guideline for inferior vena
cava lters in the treatment of patients
with venous thromboembolic disease:
Developed in collaboration with the
American college of cardiology, American
college of Chest physicians, American
college of surgeons committee on trauma,
American Heart Association, society for
vascular surgery, and society for vascular
medicine. J Vasc Interv Radiol. 2020
Oct;31(10):1529–44.
♦26. Linkins LA, Dans AL, Moores LK, Bona
R, Davidson BL, Schulman S, etal.
Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic
therapy and prevention of thrombosis,
9th ed: American college of Chest physicians evidence-based clinical practice
guidelines. Chest. 2012 Feb;141(2 Suppl):e495S–530S.
27. CRISTAL Study Group; Sidhu VS, Kelly
TL, Pratt N, Graves SE, Buchbinder R,
Adie S, Cashman K, Ackerman I, Bastiras
D, Brighton R, Burns AWR, Chong BH,
Clavisi O, Cripps M, Dekkers M, de
Steiger R, Dixon M, Ellis A, Grifth EC,
Hale D, Hansen A, Harris A, Hau R,
Horsley M, James D, Khorshid O, Kuo
L, Lewis P, Lieu D, Lorimer M, MacDessi
S, McCombe P, McDougall C, Mulford
J, Naylor JM, Page RS, Radovanovic J,
Solomon M, Sorial R, Summersell P, Tran
P, Walter WL, Webb S, Wilson C, Wysocki
D, Harris IA. Effect of aspirin vs enoxaparin on symptomatic venous thromboembolism in patients undergoing hip or knee
arthroplasty: The CRISTAL randomized
trial. JAMA. 2022 Aug 23;328(8):719–27.
doi: 10.1001/jama.2022.13416. PMID:
35997730; PMCID: PMC9399863.mcan
28. Droege ME, Droege CA, Philpott CD,
Webb ML, Ernst NE, Athota K, Wakeeld
D, Dowd JR, Gomaa D, Robinson BHR,
Hanseman D, Elterman J, Mueller EW.
Impact of antithrombin III and enoxaparin dosage adjustment on prophylactic
anti-Xa concentrations in trauma patients
at high risk for venous thromboembolism: Arandomized pilot trial. J Thromb
Thrombolysis. 2021 Nov;52(4):1117–28.
29. Gates RS, Lollar DI, Collier BR, Smith J,
Faulks ER, Gillen JR. Enoxaparin titrated
by anti-Xa levels reduces venous thromboembolism in trauma patients. J Trauma
Acute Care Surg. 2022 Jan 1;92(1):
93–7.
30. https://effectivehealthcare.ahrq.gov/
products/thromboembolism-update/
research-2017, Accessed 1/19/2023.
31. Bauersachs RM. Fondaparinux sodium:
Recent advances in the management of
thrombosis. J Cardiovasc Pharmacol Ther.
2023 Jan-Dec;28:10742484221145010.
32. Van Thiel D, Kalodiki E, Wahi R, Litinas
E, Haque W, Rao G. Interpretation of
benet-risk of enoxaparin as comparator
in the RECORD program: Rivaroxaban
oral tablets (10 milligrams) for use in
prophylaxis in deep vein thrombosis
and pulmonary embolism in patients
undergoing hip or knee replacement
surgery. Clin Appl Thromb Hemost. 2009
Jul-Aug;15(4):389–94.
33. Raskob GE, Gallus AS, Pineo GF,
Chen D, Ramirez LM, Wright RT,
etal. Apixaban versus enoxaparin for
thromboprophylaxis after hip or knee
replacement: Pooled analysis of major
venous thromboembolism and bleeding in
8464 patients from the ADVANCE-2 and
ADVANCE-3 trials. J Bone Joint Surg Br.
2012 Feb;94(2):257–64.
♦34. Schünemann HJ, Cushman M, Burnett
AE, Kahn SR, Beyer-Westendorf J, Spencer
FA, Rezende SM, Zakai NA, Bauer KA,
Dentali F, Lansing J, Balduzzi S, Darzi
A, Morgano GP, Neumann I, Nieuwlaat
R, Yepes-Nuñez JJ, Zhang Y, Wiercioch
25

266 Chapter 25 Prevention of deep venous thrombosis
https://t.me/med1917
W. American society of hematology
2018 guidelines for management of
venous thromboembolism: Prophylaxis
for hospitalized and nonhospitalized
medical patients. Blood Adv. 2018 Nov
27;2(22):3198–225. doi: 10.1182/
bloodadvances.2018022954. PMID:
30482763; PMCID: PMC6258910.
35. Krauss ES, Cronin M, Dengler N, Simonson BG, Enker P, Segal A. Lessons learned:
Using the caprini risk assessment model
to provide safe and efcacious thromboprophylaxis following hip and knee
arthroplasty. Clin Appl Thromb Hemost.
2020;26:1076029620961450.
36. Pannucci CJ, Shanks A, Moote MJ,
etal. Identifying patients at high risk
for venous thromboembolism requiring
treatment after outpatient surgery. Ann
Surg. 2012;255(6). doi: 10.1097/SLA.
0b013e3182519ccf
37. Kim NE, Conway-Pearson L, Kavanah
M, etal. Standardized risk assessment
and risk-stratied venous thromboembolism prophylaxis for patients undergoing breast operation. J Am Coll Surg.
2020;230(6):947–55.
38. Macht R, Gardner I, Talutis S,
Rosenkranz P, Doherty G, McAneny D.
Evaluation of a standardized risk-based
venous thromboembolism prophylaxis
protocol in the setting of thyroid and
parathyroid surgery. J Am Coll Surg.
2017;224(6):1029–35. doi: 10.1016/j.
jamcollsurg.2016.12.054
39. Grant PJ, Greene MT, Chopra V, Bernstein
SJ, Hofer TP, Flanders SA. Assessing
the caprini score for risk assessment of
venous thromboembolism in hospitalized medical patients. Am J Med. 2016
May;129(5):528–35.
40. Hu Y, Li X, Zhou H, Lin P, Zhang J,
Huang D, etal. Comparison between the
Khorana prediction score and Caprini risk
assessment models for assessing the risk
of venous thromboembolism in hospita-
lized patients with cancer: Aretrospective
case control study. Interact Cardiovasc
Thorac Surg. 2020 Oct 1;31(4):
454–60.
41. Zhu X, Zhang T, Zhou L, Yin X, Dong Q.
Stratication of venous thromboembolism
risk in stroke patients by Caprini score.
Ann Palliat Med. 2020 May;9(3):
631–6.
42. Razadeh R, Turgeon RD, Batterink J,
Su V, Lau A. Characterization of venous
thromboembolism risk in medical inpatients using different clinical risk assessment models. Can J Hosp Pharm. 2016
Nov-Dec;69(6):454–9. doi: 10.4212/cjhp.
v69i6.1608.
43. Tsaplin S, Schastlivtsev I, Zhuravlev
S, Barinov V, Lobastov K, Caprini JA.
The original and modied Caprini score
equally predicts venous thromboembolism
in COVID-19 patients. J Vasc Surg Venous
Lymphat Disord. 2021 Nov;9(6):
1371–81;e4.

CHAPTER
26
e
Subclavian ar
https://t.me/med1917
Management of venous thoracic
outlet syndrome
Chandu Vemuri
26.1 INTRODUCTION
Venous thoracic outlet syndrome (vTOS) is a clinical syndrome caused by dynamic compression of the subclavian
vein (SV) which can progress to deep venous thrombosis
(DVT). It comprises approximately 2%–3% of all cases of
TOS, which collectively include arterial, venous, or neurogenic TOS [1].
The SV passes through the costoclavicular space, which
is dened as the location where the rst rib and clavicle
join the sternum and includes the costoclavicular ligament and subclavius tendon (Figure26.1). In patients with
vTOS, as the upper extremity is progressively abducted,
there is impingement on the SV. This dynamic, repetitive
impingement causes trauma to the SV, resulting in chronic
injury that leads to external scar tissue and intravascular
scar formation with luminal loss and can progress to occlusion with DVT. Patients presenting with vTOS are usually
14–45years old and are otherwise healthy and physically
active [2]. Clinical history often includes a history of repetitive overhead arm use, and at times there is an inciting
event of sustained overhead activity or trauma. While many
patients may have the anatomic abnormality of a narrow
Anterior
scalene muscl
Clavicle
First rib
tery
Subclavian vein
Costoclavicular ligament
26.1 Drawing of the anterior portion of the thoracic outlet (cos-
toclavicular junction) on the right, showing the vein at the fulcrum of the lever produced by the clavicle and rst rib. Note
the proximities of the subclavian muscle and costoclavicular
ligament.
(From Sanders, R.J., and Haug, C.E., Thoracic outlet syndrome: Acommon sequela of neck injuries. 1991, Philadelphia: JB Lippincott: 1991, page
237, with permission.)
Subclavius
muscle
costoclavicular space with dynamic venous compression,
vTOS is diagnosed at the time of thrombosis of the SV. At
the time of diagnosis, many patients undergo lysis, with
follow-up venography demonstrating compression of the
SV within the thoracic outlet. Adetailed history may reveal
chronic symptoms of venous hypertension such as exertional heaviness and fatigue. Surgical correction focuses
on decompression of the costoclavicular space through
rst rib resection with or without excision of the anterior
and middle scalene muscles. Surgical approaches to rst
rib resection include para-clavicular, infra-clavicular, or
transaxillary. Venous reconstruction may be appropriate
in select patients, particularly for patients with symptomatic venous hypertension and an anatomic abnormality of
the SV not corrected by decompression alone [3]. Following surgery, systemic anticoagulation is recommended for
a minimum of 3 months and may need to be extended if
venoplasty becomes necessary to maintain venous patency
and/or relieve venous hypertension.
26.2 DIAGNOSIS
While high suspicion for vTOS can be made based on clinical history and physical exam alone, the gold standard for
diagnosis is a dynamic venogram (Figure26.2). Diagnostic
workup can include a chest X-ray to identify bony anomalies that may be leading to venous compression such as
rst rib or clavicle fracture. Oftentimes patients will have
had a CT venogram, which can reveal static compression
of the SV with luminal compromise and collateral formation (Figure26.3). Physical exam should include assessing
for symptoms of venous hypertension, focusing on arm
swelling and visible collateral veins on the arm, shoulder
girdle, or chest. While patients with vTOS often present
acutely with DVT, they will often recall a history of venous
hypertension with progressive worsening of arm swelling
and collateral vein formation that may span many years.
It should be noted that ultrasound alone is often not specic enough to diagnose vTOS, especially in a patient without any thrombotic event such as DVT or swelling. In the
asymptomatic patient, isolated venous ultrasound is an
unreliable indicator of vTOS, and therefore it is important
to conduct a thorough history and physical examination to
accurately diagnose this condition.
DOI: 10.1201/9781003328971-29
267267

268 Chapter 26 Management of venous thoracic outlet syndrome
https://t.me/med1917
Acute thrombus is most successfully treated and cleared,
while thrombus that has been present for 14 days or more
is less likely to lyse due to the chronic nature of the mature
clot, which may also have brotic changes [5]. Chun etal.
examined the role of thrombolysis on acute thrombosis in
vTOS and found improved patency (98%) in patients who
underwent thrombolysis before decompression compared
to those who received anticoagulation alone (74%) [6]. In
this analysis, all patients underwent thrombolysis within 2
26.2 Venogram in a 20 year old baseball player showing some
recanalization of an occluded subclavian vein after 24 hours of
catheter-directed thrombolysis. He underwent first rib resection
2 days later after heparin was discontinued.
26.3 3D reconstruction highlighting compression of the subcla-
vian vein in the costoclavicular space.
26.2.1 Indications for treatment
Surgical decompression is recommended for all patients
with vTOS, as it offers an improved quality of life and,
for most patients, freedom from lifelong anticoagulation. The clearest indications are for patients who present with an upper extremity DVT. Those patients should
be started on systemic anticoagulation and undergo
thrombolysis to restore venous patency. Following clot
resolution, a dynamic venogram to conrm the diagnosis, identify collaterals, and quantify the pressure gradient is an essential next step. Some patients may present
without a DVT but with chronic symptoms of venous
hypertension with conrmed dynamic compression of
the SV, and some of these patients may benet from surgical decompression [4].
26.3 THROMBOLYSIS
Axillosubclavian thrombosis is the most common clinical
manifestation of vTOS. Most commonly, acute thrombosis requires aggressive treatment with thrombolysis, which
includes instillation of a thrombolytic agent, most often
tissue plasminogen activator (tPA), within the thrombus.
weeks of the thrombotic event. Therefore, a short interval
from symptom onset to time of thrombolysis (recommend
within 1 week) is an important determinant of treatment
success and patency. The standard of care for acute DVT
includes thrombolysis; however, in patients presenting with
symptoms long after thrombosis occurs, thrombolysis provides little benet due to the chronic nature of the clot.
In these patients, decompression surgery and postoperative anticoagulation alone may be sufcient for patency
[7]. In a series of 608 patients with axillosubclavian vein
thrombosis, most of whom were treated within 6 weeks of
thrombosis with thrombolysis and immediate decompression, 97% had satisfactory results. However, in patients
who were only treated with anticoagulation alone (no
surgery), only 44% had satisfactory results, and 72% ultimately required surgical decompression due to symptoms.
Finally, only 57% of patients presenting after 6 weeks who
were treated with thrombolysis and surgery had satisfactory results, again highlighting the importance of immediate thrombolysis and decompression after thrombosis [8].
thrombolysis begins with wire passage through the thrombus. Conventional thrombolysis is performed using tPA at
1 mg/hr in combination with infusion of low-dose heparin.
Venogram is usually performed 24hours after initiation of
tPA to evaluate the effectiveness of thrombolysis. Alternatively, pharmacomechanical thrombolysis can be used and
entails infusing the thrombus with tPA and then suction to
remove the obstruction. After successful thrombolysis, surgical decompression should be performed within 2 weeks,
as improved patency rates have been obtained after performing rib resection soon after thrombolysis [9, 10].
26.4 SURGICAL DECOMPRESSION
26.4.1 Para-clavicular approach
This approach allows for a complete thoracic outlet
decompression and allows for concomitant venous repair
if needed [11, 12]. An incision is made one ngerbreadth
superior to the clavicle beginning just lateral to the sternocleidomastoid and ending at the medial edge of the trapezius muscles. The rst phase of the operation is aimed
at achieving a critical view of safety. To accomplish this,
the scalene fat pad is mobilized from the lateral border of
the internal jugular (IJ) vein. As the dissection continues, the
omohyoid muscle is divided. Then the phrenic nerve is
identied running lateral to medial over the anterior scalene muscle. Using blunt dissection, the fat pad can be
mobilized medial to lateral to the rst rib. The critical view
of safety includes the IJ, the anterior scalene muscle, the
phrenic nerve, the middle scalene muscle, the long thoracic
Once thrombosis has been conrmed with a venogram,

26.5 Follow-Up 269
https://t.me/med1917
nerve, the brachial plexus, and the rst rib. The anterior
and middle scalene muscles are then excised. Intercostal
muscles are divided off of the lateral aspect of the rst rib.
Then the posterior rst rib is divided with the plexus protected. For the second part of the operation, an infraclavicular incision is made extending from the lateral edge of the
sternum for 3–5cm. The pectoralis major muscle is identied and then a vascular plane created between the clavicular and sternal components. In this space the rst rib is
found, intercostal muscles removed, and then the anterior
rib is divided. Then subclavius muscle tendon and costoclavicular ligament are removed. For the third portion of the
operation, an external venolysis is performed through both
incisions and then a venogram done to assess for venous
patency. If the vein is patent without signicant compression, then the incisions are closed. However, if the patient
has symptoms of venous hypertension and the vein has a
high-grade stenosis or occlusion, then direct venous repair
can be done with either a bovine pericardial patch angioplasty or a venous bypass as dictated by the type of lesion.
26.4.2 Infraclavicular approach
Another operation strategy with comparable patency and
complication rates when done by high-volume surgeons
is the infraclavicular approach [13]. In the infraclavicular
approach, only the anterior half of the rst rib is partially
resected through an infraclavicular incision [14]. This is
accompanied by resection of the subclavius tendon and
anterior and middle scalene muscle division. For long subclavian vein stenoses (>2 cm), the infraclavicular incision
may need to be extended medially to the midline. Optimal
timing of surgical intervention relative to thrombolysis was
determined by Molina etal., who compared thrombolysis
followed by immediate decompression (within 2 weeks) versus decompression 2 weeks to 3 months after thrombolysis [9]. Patients in this second group received an additional
round of thrombolysis in the time period leading up to surgery, and all patients underwent decompression through the
infraclavicular approach. Strikingly, 100% of patients who
underwent immediate surgery after thrombolysis had successful restoration of inow, in contrast to a 29% success
rate in patients who had delayed decompression. All patients
were managed postoperatively with 8 weeks of anticoagulation. In this series, 80% of patients also underwent venous
reconstruction with vein patch at the time of decompression,
which may contribute to the comparable patency rates of the
infraclavicular approach with the supraclavicular approach.
26.4.3 Transaxillary approach
The transaxillary approach for vTOS is associated with
low complication rates and high SV patency rates [15]. In
this approach, the patient is placed in a lateral decubitus
position with the affected side up. The arm and axillary are
prepped and then the arm is placed in an impervious stockinette. At our institution, we make use of an arm retractor,
but an assistant can also be used. In either case, the arm
should be rested every 20 minutes to prevent hyperabduction injury on the nerves. Atransverse incision between the
latissimus dorsi and the pectoralis major muscles is made.
The incision is carried down through the clavipectoral
fascia until the edge of the chest wall is reached. In cases of
vTOS, there can be signicantly large collaterals running
through the axillary space. Typically, these can be preserved
but may require ligation if their presence will hinder full
visualization of deeper structures. Once dissection is carried
down the chest wall, blunt dissection can often be carried
up to the level of the rst rib. The subclavian vein can usually be identied and followed to where it runs near the rst
rib. The visualization is aided by narrow long retractors,
but care should be taken to avoid placing this directly on
the brachial plexus. At this point, the subclavian vein, anterior scalene muscle, and subclavian artery should be clearly
visualized. The phrenic nerve will course lateral to medial
and is often above the cephalad portion of the dissection,
though care should be taken to identify any abnormal
courses within the surgical eld. ACobb elevator is then
used to separate the intercostal muscles from the anterior
border of the rst rib. Once this is completed both medially and laterally, the parietal pleural can also be bluntly
separated from the underside of the rib, often with the
backside of the Cobb elevator. Aright angle is then placed
around the anterior scalene to isolate it, ensuring there are
no branches of the subclavian artery, vein, or phrenic nerve
within the anticipated area of dividing. The anterior scalene
is then sharply divided. The Cobb or periosteal elevator can
be used to divide the middle scalene off the rib, taking care
not to injure the long thoracic nerve, which may be a single nerve or three separate nerves at this point. An angled
long-handled rib cutter is then inserted, and the rst rib is
divided rst anteriorly medial to the subclavian artery. The
subclavius muscle or costoclavicular ligament may require
division to allow for medial placement of the rib cutter.
Once completed, the bone can be divided posteriorly with
the rib cutter. Arongeur can then be used to ensure there
is a smooth bone edge without impingement on the lower
nerve root of the brachial plexus. Afocused venolysis of the
subclavian vein can be performed with Metzenbaum scissors to ensure any remaining bands or compressive scars
are removed to allow for full venous expansion. Once all
dissection is completed and the rib is removed, the wound is
lled with normal saline and the anesthesiologists are asked
to perform a Valsalva maneuver to evaluate for violation of
the pleura. This may be apparent if a large volume of the
instilled saline is lost in the wound or if there are air bubbles with Valsalva. If a violation is noticed, there are several
mechanisms for treating, which involve placing a suction
catheter through the pleural defect and evacuating the uid
in the chest. Postoperatively, the timeline for restarting anticoagulation is not well studied. In our practice, patients are
maintained on aspirin for 5 days and then restart their oral
anticoagulation on postoperative day 6.
26.5 FOLLOW-UP
Postoperative care after vTOS decompression should focus
on returning patients to full unrestricted activity. During
the acute postoperative phase, it is important to assess for
complications. These include but are not limited to postoperative hematoma, injury to the brachial plexus, injury to
the phrenic nerve, lymph leak, postoperative venous thrombosis, pneumothorax, and pleural effusion. Postoperative
26

270 Chapter 26 Management of venous thoracic outlet syndrome
https://t.me/med1917
protocols are specic to the type of surgical decompression
and can include closed suction drains and pain infusion
catheters. When safe from an operative standpoint, systemic anticoagulation should be resumed and maintained
for a minimum of 3 months from the time of DVT. Early
activity is important, and in that regard inpatient physical
therapy is initiated the day after the operation. After discharge from the hospital, the patient should be seen on a
scheduled basis to assess for complications, follow progress with PT, and assess for venous patency. In patients
with a patent vein, 3 months out from the initial DVT,
anticoagulation can be safely stopped. However, if patients
have persistent or recurrent symptomatic venous lesions,
it is reasonable to extend anticoagulation and/or perform
endovascular venoplasty.
26.6 CONCLUSION
vTOS is an uncommon condition that can have a significant impact on young, healthy patients, and therefore
timely anticoagulation, lysis, and decompression can allow
patients to resume full activity and be free from lifelong
anticoagulation. The standard of care for treating vTOS
should begin with systemic anticoagulation and thrombolysis within 14 days, followed by surgical decompression.
The surgical approach can be either para-clavicular, infraclavicular, or transaxillary. Specic postoperative care algorithms are used to minimize complications after surgery,
and routine postoperative care includes anticoagulation
to ensure axillosubclavian patency, as well as appropriate
follow-up.
Consensus Statements 26.0 of the American Venous Forum on the management of venous thoracic outlet syndrome
No. Consensus Statements
26.1 Patients with new upper extremity DVT without an indwelling catheter or alternative cause should undergo catheter-directed
thrombolysis and venography to evaluate for venous thoracic outlet syndrome.
26.2 Stent placement to reduce subclavian vein narrowing should be avoided in patients with vTOS who have not yet had a surgical decompression of the thoracic outlet.
26.3 Following thrombolysis and venography, patients with identied vTOS should undergo surgical decompression of the thoracic outlet within 2–6 weeks to reduce the risk of recurrence.
26.4 Surgical decompression through the supraclavicular, infraclavicular, or transaxillary approaches are equally effective for
vTOS, and the surgeon should choose the method with which they are the most comfortable.
26.5 Following surgical decompression, patients should resume anticoagulation to complete a 3-month total treatment course
from initial diagnosis.
26.6 A longer course (6 months) of anticoagulation can be considered for patients with persistent axillosubclavian vein occlusion
to allow for recanalization.
26.7 Patients with chronic, partially occlusive thrombus in the axillosubclavian vein following rst rib resection should be evaluated
for venography and balloon venoplasty to restore the normal vein contour.
REFERENCES
★ Systematic review
1. Skirven, T.M., etal., Rehabilitation of the
hand and upper extremity. 7th ed. 2020,
Philadelphia: Elsevier.
2. Cook, J.R., and R.W. Thompson, Evalua-
tion and management of venous thoracic
outlet syndrome. Thorac Surg Clin, 2021.
31(1): p.27–44.
3. Samoila, G., C.P. Twine, and I.M. Williams, The infraclavicular approach for
Paget–Schroetter Syndrome. Ann R Coll
Surg Engl, 2018. 100(2): p.83–91.
4. Bozzay, J.D., etal., Infraclavicular tho-
racic outlet decompression compared to
supraclavicular thoracic outlet decompression for the management of venous
thoracic outlet syndrome. Ann Vasc Surg,
2020. 65: p.99.
5. Suresh, V., Venous clot lysis and sten-
ting.Hematol Am Soc Hematol Educ
Program, 2015. 2015(1): p.210–214.
6. Chun, T.T., etal., Preoperative throm-
bolysis is associated with improved
vein patency and functional outcomes
after rst rib resection in acute Paget–
Schroetter syndrome. J Vasc Surg, 2022.
76(3): p.806–813, e1.
7. de León, R., etal., First rib resection and
scalenectomy for chronically occluded
subclavian veins: What does it really do?
Ann Vasc Surg, 2008. 22(3): p.395–401.
8. Urschel, H.C., and A.N. Patel, Surgery
remains the most effective treatment for
Paget–Schroetter syndrome: 50years’
experience. Ann Thorac Surg, 2008.
86(1): p.254–260; discussion 260.
9. Molina, J.E., D.W. Hunter, and C.A. Dietz,
Paget–Schroetter syndrome treated with
thrombolytics and immediate surgery. J
Vasc Surg, 2007. 45(2): p.328–334.
★
10. de Kleijn, R.J.C.M., etal., Timing of tho-
racic outlet decompression after thrombolysis for primary upper extremity deep
venous thrombosis: Asystematic review.
Ann Vasc Surg, 2020. 66: p.654–661.
11. Stanley, J.C., F.J. Veith, and T.W. Wakeeld, Current therapy in vascular and
endovascular surgery. 5th ed. 2014,
Philadelphia, PA: Elsevier/Saunders. xxxi,
1008 pages.
12. Maxey, T.S., etal., Safety and efcacy of
the supraclavicular approach to thoracic
outlet decompression. Ann Thorac Surg,
2003. 76(2): p.396–399; discussion
399–400.
13. Madden, N., etal., Evolving strategies for
the management of venous thoracic outlet
syndrome. J Vasc Surg Venous Lymphat
Disord, 2019. 7(6): p.839–844.
14. Cronenwett, J.L., and K.W. Johnston,
Rutherford’s vascular surgery. 8th ed.
2014, Philadelphia, PA: Saunders/Elsevier.
2 volumes (xxxviii, 2570, lxvi pages).
15. Faber, L.L., R.L. Geary, K.Z. Chang,
M.P. Goldman, J. Freischlag, and G.
Velazquez, Excellent results seen with
both transaxillary and infraclavicular
approaches to rst rib resection in
patients with subclavian vein thrombosis.
J Vasc Surg Venous Lymphat Disord,
2023 Jan. 11(1): p.156–160.

CHAPTER
27
https://t.me/med1917
Acute central venous thrombosis in the
setting of central lines, pacemaker
wires, and dialysis catheters
Justin M. Robbins, Anil Hingorani, and Enrico Ascher
27.1 INTRODUCTION
Acute central venous thrombosis (CVT) is an important
topic with a global effect. It can be divided into two causes:
primary or secondary. Whereas primary causes are due to
effort thrombosis or thoracic outlet syndrome, secondary
causes are mostly due to either malignancy or indwelling
catheters. Secondary causes of thrombosis have become the
most likely source of this disease process.
Acute CVT lends itself to a signicant discussion
because the use of central venous access, for the placement
of catheters and treatment of cardiac arrhythmias with
pacing wires and debrillators, has been rapidly increasing
worldwide during the last few decades. The most recent
data estimate approximately 5million central venous catheters (CVCs) are inserted yearly in the United States and
that there are over 2 million patients with pacemakers
worldwide.
ids, medications, blood products, and antibiotics; perform
hemodialysis; monitor hemodynamics; and provide parenteral nutrition. All of these instruments carry signicant
potential to cause central venous trauma, which can lead
to CVT.
Upper extremity deep vein thrombosis (UEDVT)
accounts for approximately 5% of all cases of DVT, with
the majority being attributed to secondary causes such
as cannulation and malignancy.
large prospective registry of consecutive patients with
acute symptomatic deep vein thrombosis (DVT), the Computerized Registry of Patients with Venous Thromboembolism (RIETE), the authors identied the prevalence of
UEDVT as 512 among 11,564 DVT patients (4.4%). They
also demonstrated that 228 of those 512 UEDVT patients
(45%) had catheter-related UEDVT.
has been associated with complications of pulmonary
embolism (PE), post-thrombotic syndrome, and death.
As a consequence, our discussion in this chapter will
focus on acute CVT in the setting of upper extremity central venous lines, dialysis catheters, and pacemaker wires.
The diagnosis and treatment of lower extremity DVT
(LEDVT) are discussed elsewhere.
1,2
They are utilized to administer various u-
3
In a study based on the
4
Furthermore, UEDVT
5
27.2 EPIDEMIOLOGY
27.2.1 Demographics
The RIETE registry comprises the largest amount of prospectively collected data on patients with DVT. Its review
has demonstrated that patients with UEDVT compared
to patients with LEDVT are younger (54 years ± 19 vs
66years ± 17), more often male (59% vs 52%), weigh less
(71 kg ± 14 vs 74 kg ± 14), have less frequent recent history
of DVT (7% vs 17%), and more commonly have cancer
(38% vs 20%). Tohme etal. conducted a single-center retrospective study of 1009 upper extremity venous duplex
studies with multinomial regression, nding hypertension,
chronic kidney disease, malignancy, CVC, and peripherally
inserted central venous catheters (PICCs) as independent
predictors of UEDVT.
In a study by Hingorani etal. in 1997, 170 patients with
UEDVT were analyzed. The average age of the patients
was 64 (± 17) years, they were more often females (66%),
and they had a history of cancer (22%). The overall mortality rate in this group was 29% at 2 months.
Ascher et al. conducted a retrospective study evaluating
210 UEDVT identied on duplex. They were unable to nd
a correlation between site of insertion and PE or mortality. However, they did note that there was a high mortality
rate associated with UEDVT, and APACHE III scores were
calculated for the patients, which correlated for the high
observed mortality, suggesting it was a result of underlying
medical problems.
evaluated 48 LEDVT and 35 UEDVT, nding that UEDVT
had a signicantly higher proportion of comorbidities such
as CAD (25.7% vs 13.1%, p=0.16), CHF (20% vs 6.6%,
p=0.09), and malignancy (60% vs 42.6%, p=0.13). They
also found that UEDVT had a signicantly higher all-cause
mortality than LEDVT (33.3% vs 4.9%, p=0.0119).
27.2.2 CVC-related UEDVT
In the same study, Hingorani etal., utilizing duplex ultrasonography as part of the workup for arm swelling or
6
5
In 2005,
7
Furthermore, in 2020, Rokosh et al.
8
DOI: 10.1201/9781003328971-30
271271

272 Chapter 27 Acute CVT in the setting of central lines, pacemaker wires, and dialysis catheters
https://t.me/med1917
PE, found 170 patients with UEDVT. This retrospective
study demonstrated concurrent CVC or pacemakers in
110 (65%) of UEDVT patients.
UEDVTs were associated with CVCs ranging from 32%
to 70%.
9–10
Finally, a review by Kuter demonstrated that
5
Other studies have shown
patients with CVC-related infection had a greater likelihood of having thrombosis than those patients without
CVC-related infection, with an odds ratio of 4.1 (95% CI
1.5–11.4).
11
27.2.3 Cancer population
In 2004, Kuter evaluated CVC-related thrombosis (CRT)
in the cancer population based on 12 studies with 607
patients and demonstrated that CRT occurred in 41%
(range = 12–74%) of all cancer patients. The authors
demonstrated a higher incidence of asymptomatic
thrombi as compared to symptomatic thrombi: 29%
(range 5%–62%) and 12% (range 5%–54%), respec-
11
tively.
The same paper referenced an article in which
longitudinal analysis was performed on cancer patients to
evaluate the timing of thrombosis. Serial venography was
performed at 8, 30, and 105 days after catheter insertion
on 95 patients. The authors found that by 8, 30, and 105
days, 64%, 65%, and 66% of all CVCs were found to
have thrombosis, respectively. However, in 2015 Leung
et al. performed a systematic review of patient-related
risk factors to determine if malignancy was associated
with CRT, where he identied eight studies with a total
of 1999 patients, with no effect detected in six studies.
In two of the studies there was a positive association
between malignancy (OR 4.1 95% CI 1.9–8.9 P ≤ 0.001)
and CRT on multivariate analysis (OR 1.953 95% CI
1.014–3.761 P=0.05). They also evaluated chemotherapy as a risk factor and identied 11 studies, with ndings
of 3 studies showing it was a signicant risk factor for
CRT with an OR ranging from 3.19 to 4.109. Six of the
studies reported no association.
12
27.3 CLINICAL PRESENTATION
The most common presentation of patients with UEDVT
is asymptomatic. The symptoms of UEDVT are usually
reective of the local effects of the thrombosis or embolization. In symptomatic patients, one or more of the following may be present: swelling of the extremity, face and
neck; pain of the extremity or neck; numbness; headache;
paresthesia; engorgement of chest wall, neck, and extremity veins; jaw pain; and erythema.
highly variable among patients and can range from mild
to debilitating. In rare cases, phlegmasia cerulea dolens has
also been reported.
20
27.3.1 Pulmonary embolism
The incidence of PE is lower in UEDVT compared to
LEDVT. Joffe etal. performed a prospective studyevaluating 324 patients with UEDVTs with CVCs and found
that PE was less frequently found in UEDVT vs LEDVT
(3% vs 16%, p < 0.001).
attributed the risk of PE to be 5% of all UEDVT and up to
16
In another study, the authors
13–19
Symptoms can be
20% in patients with CVC-associated UEDVT,while other
studies have demonstrated the risk of PE ranging between
4% and 15%.
5,21–22
Additionally, ndings from the RIETE
registry have demonstrated that patients with UEDVT are
associated with less severe symptoms of PE as compared
to those with LEDVT (9.0% vs 29%), OR 0.24 (95% CI
0.18–0.33).
4
27.3.2 Post-thrombotic syndrome
Post-thrombotic syndrome (PTS) has been dened in studies as persistent signicant swelling with pitting edema and
is a known complication of UEDVT. In 2018, Thiyagarajah etal. conducted a systematic review and meta-analysis
regarding PTS with UEDVT and identied 22 studies with
a total of 944 patients. The pooled proportion of PTS using
a random effects model was 19.4% (95% CI 11.3–27.6).
They then analyzed the recurrence of UEDVT in 37 studies
with a total of 2552 patients and found the overall proportion of recurrent DVT was 7.5% (95% CI 4.1–10.9), with
a higher proportion in secondary vs primary UEDVT (15.9
vs 6.4%).
3
27.4 RISK FACTORS
27.4.1 Risk with CVC
Risk factors for CRT can be related to patient comorbidities, insertion, catheter, or a combination of any of these
factors. In 1970, Tilney and Grifths documented the rst
series of patients with indwelling catheter-related UEDVT.
Their study included 48 patients over a 25-year period
who were found to have UEDVT, with 31 of 48 UEDVT
(64.6%) being associated with indwelling catheters.
That study forewarned the increasing incidence of such
occlusions as methods for long-term central venous access
become more widely used. Valeriani et al. conducted a
systematic review and analyzed 20 observational studies including 1473 patients receiving anticoagulation for
UEDVT, with the presence of CVC being the most common risk factor found (855/1407 patients [60.8%]; 16
studies).
23
In 2015, Winters etal. performed a case-cohort
study of hospital-acquired VTE evaluating 64,034 admissions with 299 cases of VTE identied. They found that
UEDVT had an incidence of 1.4 per 1000 admissions and
that CVC was associated with a 14-fold increased risk of
UEDVT (OR 13; 95% CI 0.8–2.1).
24
Some studies have
evaluated if there is any correlation between the type of
the catheter and the procedure itself. In 1988, Horattas
et al. retrospectively reviewed data of all patients who
presented to their facility with the diagnosis of UEDVT
during a period of six years.They demonstrated that the
risk of UEDVT increased with multiple punctures, largebore catheters, the type of catheter material, and duration
of placement of the catheter.
25
In 2014, Geerts identied
multiple studies that found increased rates of CRT with
the use of larger, multilumen, and peripherally inserted
catheters in patients with cancer receiving chemother-
26
apy.
The 2013 review article by Murray etal. demonstrated a
positive correlation with patient-related risk factors includ-
19

27.4 Risk factors 273
https://t.me/med1917
ing previous history of venous thromboembolism, inherited thrombophilia, malignancy, and presence of an acute
infection.
14
Furthermore, they cited a prospective study on
hematological malignancy in which CRT increased in the
presence of catheter-related infection. That study was performed using 105 consecutive patients undergoing intensive chemotherapy and addressed the risk of CVC-related
infection and thrombosis. All patients with clinical exam of
the upper extremity suspicious for DVT underwent duplex
ultrasonography or venography. The authors demonstrated
the risk of thrombosis increased markedly in those with
catheter-related infection compared to those without catheter-related infection (relative risk 17.6, 95% CI 4.1–74.1).
Thus, it is prudent to understand that catheter infection
has a signicant role in CVC-related thrombosis.
27.4.2 Risk with PICC
PICCs have been able to provide convenient long-term
intravenous access for patients. In a retrospective analysis,
the authors reviewed all upper extremity venous duplex
ultrasonography examinations completed over a 1-year
period at their vascular lab to identify patients with newly
diagnosed UEDVT and a PICC placement ≤30 days from
the examination.
scans, 154 (18.5%, 138 patients) scans were positive for
UEDVT. PICC-associated DVT occurred in 54 of the 154
(35%) patients with UEDVT. These 54 PICC-associated
DVTs occurred among the 1862 (2.6%) patients with PICC
line placement during that time period. Previous large retrospective studies have also demonstrated the incidence of
UEDVT ranges from 1.6% to 3.5% among all PICC placements. This study also found that large PICC diameter (≥5
Fr) had an odds ratio of 3.9 (95% CI 1.1–13.9; P=0.037)
and concurrent malignancy had an odds ratio of 4.1 (95%
CI 1.9–8.9; P ≤0.001) to develop UEDVT. The authors
concluded that although the percentage of PICC-associated UEDVT is low, the increasing number of PICC placements lends itself to the overall increase in the number of
patients who experience PICC-associated UEDVT. Other
authors have addressed the risk of UEDVT associated with
PICC as compared to other CVCs. Chopra et al. completed a systematic review and documented that from the
meta-analysis of 11 studies with 3788 patients, PICC lines
were associated with an increased risk of DVT compared
to other CVCs (OR 2.55, 95% CI 1.54–4.23; P ≤ 0.0001).
The number needed to harm for PICC compared to CVC
was 26 (95% CI 13–71).
In another study, PICC line diameters and ow rates
were analyzed. The authors demonstrated in a uid analysis model that the risk of thrombosis increased as a function of catheter size. This study documented that venous
ow may be reduced by up to 80% with a 6 Fr catheter.
Additionally, recent prospective studies have also shown
an increased rate of symptomatic DVT with increasing
PICC size from 4 Fr (1.0%–2.9%) to 6 Fr (8.8%–9.8%).
Recently, Walusimbi etal. performed a retrospective study
evaluating 6607 trauma patients at a level 1 trauma center
to identify risk factors for UEDVT in trauma patients. They
found there was a higher association of UEDVT in patients
who had a higher mean injury severity score (22.06 +/–
8.84 vs 18.81 +/– 9.99; p=0.014), a TBI (83% vs 54.1%;
27
They found that of the 831 completed
28
29
p ≤ 0.001), or a PICC line during their hospitalization
(94.3% vs 52.5%; p ≤ 0.001).
30
While PICCs are useful in the setting of long-term IV
access for patients who may require medication or nutrition support for weeks in the home or community setting,
the risk of UEDVT should be considered. The decision for
placement of PICC lines should be considered on a case-bycase basis. However, the benets of a PICC line in patients
who need long-term IV access, such as decreased rate of
infection, compared to central lines likely outweigh the risk
of UEDVT formation. Patients with PICC lines should be
monitored closely for signs and symptoms of UEDVT and
treated promptly upon diagnosis.
27.4.3 Risk factors in pediatrics
A large retrospective cohort study to examine the incidence
of CVC thrombosis in pediatric patients found 3.2% of
CVCs were associated with thrombosis (2.8% DVT and
0.4% supercial vein thrombosis). This review examined
24 studies with 11,479 children. The study reported an
incidence of 50% of all venous thromboses in children
occur in those patients with CVC.They demonstrated in
815 patients with catheters that increasing age (OR 1.08,
95% CI 1.03–1.13; P=0.002), renal dialysis (OR 3.2, 95%
CI 1.09–9.66; P=0.035), and diagnosis of inammatory
bowel disease (IBD) or short bowel syndrome (OR 4.3,
95% CI 1.2–15.0; P=0.02) increased the risk of thrombo-
31
In addition, they found that the risk of CVC-related
sis.
venous thrombosis ranges from 1.7% to 81.0% in various
subgroups (such as patients with cancer, hemophilia, critically ill, children with IBD, and hospitalized and outpatient
settings).
27.4.4 Risk with pacemaker wires
Patients with cardiac devices such as wires for pacing
or debrillation are also at signicant risk for UEDVT.
The rst study to document symptomatic UEDVT associated with transvenous pacing documented 5 patients
with symptomatic UEDVT of the 212 patients with pacemakers (2%). These patients were treated with anticoagulation and arm elevation.
performed a study to document the interval of time
between pacemaker placement and UEDVT by performing routine duplex ultrasonography before placement
and then at 3, 6, and 12 months after placement. The
study demonstrated that UEDVT was seen in 34 of
145 patients (23%). Most patients were found to have
UEDVT within the rst 3 months of lead implantation
(20/34, 59%).
33
The study also demonstrated a relative
risk of 3.8 (95% CI 1.0–15.0) for risk of thrombosis in
patients with multiple leads (27.4%) as compared with a
single lead (7.2%).
The study by Korkeila et al. found that pacemaker
implantation induced a transient hypercoagulable state,
but the patient’s degree of hypercoagulability did not predict subsequent venous thromboembolism. The authors
concluded that thrombosis formation with pacemaker
leads was likely to involve the three components of the
Virchow triad: stasis, hypercoagulability, and endothelial
damage, which has been echoed by other studies.
32
More recently, van Rooden
34
27
Соседние файлы в папке Библиотека им академика М.И. Перельмана
